Appili Therapeutics Inc.
APLI.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 77.40K | 3.40K | -- | 8.70K | 351.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 77.40K | 3.40K | -- | 8.70K | 351.60K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 77.40K | 3.40K | -- | 8.70K | 351.60K |
| SG&A Expenses | 321.20K | 479.30K | 558.70K | 621.20K | 459.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.55M | 1.99M | 2.04M | 1.80M | 1.76M |
| Operating Income | -1.47M | -1.98M | -2.04M | -1.79M | -1.41M |
| Income Before Tax | -381.70K | -544.30K | -1.16M | -811.80K | -107.50K |
| Income Tax Expenses | -7.10K | 900.00 | -- | 6.60K | 4.50K |
| Earnings from Continuing Operations | -374.60K | -545.10K | -1.16M | -818.50K | -112.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -374.60K | -545.10K | -1.16M | -818.50K | -112.00K |
| EBIT | -1.47M | -1.98M | -2.04M | -1.79M | -1.41M |
| EBITDA | -1.47M | -1.98M | -2.03M | -1.79M | -1.41M |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.27M | 121.27M |
| Average Diluted Shares Outstanding | 121.27M | 121.27M | 121.27M | 121.27M | 121.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
